Potential applications of nanotechnologies to Parkinson's disease therapy

Parkinsonism and Related Disorders

Volumn 14, Issue 5, 2008, Pages 383-392

  Linazasoro, G ^a  

^a Centro de Investigacion Parkinson   (Spain)

Author keywords

Biosensors; Drug delivery systems; Nanotechnologies; Parkinson's disease; Transplantation; Vectors

Indexed keywords

AMANTADINE; APOMORPHINE; BUDIPINE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; FULLERENE; LEVODOPA; LISURIDE; NANOPARTICLE; NEUROTRANSMITTER; ROTIGOTINE; TYROSINE 3 MONOOXYGENASE;

ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; CELL SURVIVAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; DYSKINESIA; GENE TARGETING; HUMAN; LIPID PEROXIDATION; NANOBIOTECHNOLOGY; NANOTECHNOLOGY; NERVE REGENERATION; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY; PARKINSON DISEASE;

EID: 47149118569     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2007.11.012     Document Type: Review

References (97)

1. Koller W.C., and Tse W. Unmet needs in Parkinson's disease. Neurology 62 Suppl. 1 (2004) S1-S8
2. Silva G.A. Neuroscience nanotechnology: progress, opportunities and challenges. Nature Rev Neurosci 7 (2006) 65-74
3. Editorial. Why small matters. Nature Biotechnol 21 (2003) 1113
4. Morris K. New-wave neurotechnology: small-scale makes big promises. Lancet Neurol 3 (2004) 202
5. Lang A.E., and Lozano A.M. Parkinson's disease. N Engl J Med 339 (1998) 1130-1143 [part II]
6. Linazasoro G. Cell therapy for Parkinson's disease: only young patients allowed?. Cell Transplant 15 (2006) 463-473
7. Schapira A.H.V. Present and future drug treatment for Parkinson's disease. J Neurol Neurosurg Psychiatry 76 (2005) 1472-1478
8. Berton O., and Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nature Rev Neurosci 7 (2006) 137-151
9. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 47 (2002) 27-38
10. Linazasoro G. Clozapina. Neurología 10 (1995) 92-99
11. Verhagen Metman L., Del Dotto P., LePoole K., Konitsiotis S., Fang J., and Chase T.N. Amantadine for levodopa-induced dyskinesias. A 1-year follow-up study. Arch Neurol 56 (1999) 1383-1386
12. Przuntek H., and Müller T. Clinical efficacy of budipine in Parkinson's disease. J Neural Transm Suppl 56 (1999) 75-82
13. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
14. Floresco S.B., West A.R., Ash B., Moore H., and Grace A.A. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 6 (2003) 968-973
15. Ruiz Ortega J.A., and Linazasoro G. Estructura y función de los receptores dopaminérgicos. Mecanismos de transducción. In: Luquin R. (Ed). "Receptores dopaminérgicos: de la estructura a la función" (2004), Entheos, Madrid 51-88
16. Parish C.L., Finkstelstein D.I., Drago J., Borrelli E., and Horne M.K. The role of dopamine receptors in regulating the size of axonal arbors. J Neurosci 21 (2001) 5147-5157
17. Antonini A., Schwarz J., Oertel W.H., Beer H.F., Madeja U.D., and Leenders K.L. [11C] raclopride and PET in previously untreated patients with Parkinson's disease: influence of l-Dopa and lisuride therapy on striatal dopamine D2 receptors. Neurology 44 (1994) 1325-1329
18. Shen K.Z., Zhu Z.T., Munhall A., and Johnson S.W. Dopamine receptor supersensitivity in rat subthalamus after 6-hydroxydopamine lesions. Eur J Neurosci 18 (2003) 2967-2974
19. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol 47 Suppl. 1 (2000) 90-104
20. Calon F., Tahar A.H., Blanchet P.J., Morisette M., Grondin R., Goulet M., et al. Dopamine receptor stimulation: behavioural and biochemical consequences. Trends Neurosci 23 (2000) S92-S100
21. Linazasoro G. Pathophysiology of motor complications in Parkinson's disease: postsynaptic mechanisms are crucial. Arch Neurol 64 (2007) 137-140
22. Johnston T.H., Fox S.H., and Brotchie J.M. Advances in the delivery of treatments for Parkinson's disease. Expert Opin Drug Deliv 2 (2005) 1059-1073
23. Katzenschlager R., Hughes A., Evans A., Manson A.J., Hoffman M., Swinn L., et al. Continuous subcutaneous apomorphine improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 20 (2005) 151-157
24. Nyholm D., Nilsson Remahl A.I.M., Dizdar N., Constatinescu R., Holmberd B., Jansson R., et al. Duodenal levodopa infusion monotherapy versus oral polypharmacy in advanced Parkinson's disease. Neurology 64 (2005) 216-223
25. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 65 Suppl. 1 (2005) S3-S5
26. Nugroho A.K., Li G., Grossklaus A., Danhof M., and Bouwstra J.A. Transdermal iontophoresis of rotigotine: influence of concentration, temperature and current density in human skin in vitro. J Control Release 96 (2004) 159-167
27. Langer R. Drug delivery abd targeting. Nature 392 (1998) S5-S10
28. Giacomelli C., Lafitte G., and Borsali R. Polycaprolactone-b-poly(ethylene oxide) biocompatible micelles as dynamic light scattering drug delivery nanocarriers: dynamic light scattering and fluorescence experiments. Macromolecular Symposia 229 (2005) 107-117
29. Mecerreyes D., Stevens R., Nguyen C., Bengoetxea M., Grande H., and Pomposo J.A. Synthesis and characterization of polypyrrole-graft-poly(ε-caprolactone) copolymers: new electrically conductive nanocomposites. Synthetic Met 126 (2002) 173-178
30. Wang X., Gu X., Yuan C., Chen S., Zhang P., Zhang T., et al. Evaluation of biocompatibility of polypyrrole in vitro and in vivo. J Biomed Mater Res A 68A 3 (2004) 411-422
31. Marcilla R., Sanchez-Paniagua M., Lopez-Ruiz B., Lopez-Cabarcos E., Ochoteco E., Grande H., et al. Synthesis and characterization of new polymeric ionic liquid microgels. J Polym Sci Polymer Chem 44 (2006) 3958-3965
32. LaVan D.A., McGuire T., and Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol 10 (2003) 1184-1191
33. Ochoteco E., Murillo N., Rodriguez J., Pomposo J.A., and Grande H. In: Dickey E.C. (Ed). Encyclopaedia of sensors. Intrinsically conducting polymers based electrochemical vol. X (2006), American Scientific Publishers 1-19
34. Tao S.L., and Desai T.A. Microfabricated drug delivery systems: from particles to pores. Adv Drug Deliv Rev 55 (2003) 315-328
35. Kerner W. Implantable glucose sensors: present status and future developments. Exp Clin Endocrinol Diabetes 109 (2001) S341-S346
36. Withtman R.M. Probing cellular chemistry in biological systems with microelectrodes. Science 311 (2006) 1570-1574
37. Zhang Y., Schlachetzki F., Zhang Y.F., Boado R.J., and Pardridge W.M. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum Gene Ther 15 (2004) 339-350
38. Olivier J.C. Drug transport to brain with targeted nanoparticles. NeuroRx 2 (2005) 108-119
39. Rodríguez M.C., Gorospe A., Linazasoro G., Ramos E., Rodriguez P., and Obeso J.A. Bilateral deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neurology 55 Suppl. 6 (2000) 45-51
40. Kortekaas R., Leenders K.L., Van Oostrom J.C.H., Vaalburg W., Bart J., Willemsem A.T.M., et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57 (2005) 176-179
41. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., and Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70 (2001) 1-20
42. Pardridge W.M. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx 2 (2005) 129-138
43. Lockman P.R., Mumper R.J., Khan M.A., and Allen D.D. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 28 (2002) 1-13
44. Linazasoro G. Neuroprotection and neurorescue in Parkinson's disease: love story or mission impossible?. Exp Rev Neurother 2 (2002) 403-416
45. Dugan L.L., Lovett E.G., Quick K.L., Lotharius J., Lin T.T., and O'Malley K.L. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord 7 (2001) 243-246
46. Oberdorster E. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ Health Perspect 112 (2004) 1058-1062
47. Sayes C.M., Gobin A.M., Ausman K.D., Mendez J., West J.L., and Colvin V.L. Nano-C60 cytotoxicity is due to lipid peroxidation. Biomaterials 26 (2005) 7587-7595
48. Hartig W., Paulke B.R., Varga C., Seeger J., Harkany T., and Kacza J. Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting beta-amyloid in Alzheimer's disease. Neurosci Lett 338 (2003) 174-176
49. Gross C.G. Neurogenesis in the adult brain: death of a dogma. Nature Rev Neurosci 1 (2000) 67-72
50. Alvarez-Buylla A., and Garcia-Verdugo J.M. Neurogenesis in adult subventricular zone. J Neurosci 22 (2002) 629-634
51. Zhao M., Momma S., Delfani K., Carlen M., Cassidy R.M., Johansson C.B., et al. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci U S A 100 (2003) 7925-7930
52. Frielingsdorf H., Schwarz K., Brundin P., and Mohapel P. No evidence for new dopaminergic neurons in the adult mammalian substantia nigra. Proc Natl Acad Sci U S A 101 (2004) 10177-10182
53. Yoshimi K., Ren Y.R., Seki T., Yamada M., Ooizumi H., and Onodera M. Possibility for neurogenesis in substantia nigra of parkinsonian brain. Ann Neurol 58 (2005) 31-40
54. Freundlieb N., Francois C., Tandé D., Oertel W.H., Hirsch E.C., and Höglinger C.U. Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J Neurosci 26 (2006) 2321-2325
55. Höglinger G.U., Rizk P., Muriel M.P., Duyckaerts C., Oertel W.H., Caille I., et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7 (2004) 726-735
56. Bharali D.J., Klejbor I., Stachowiak E.K., Dutta P., Roy I., Kaur N., et al. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci U S A 102 (2005) 11539-11544
57. Diaz-Hernández M., Torres-Peraza J., Salvatori-Abarca A., Moran M.A., Gómez-Ramos P., Alberch J., et al. Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J Neurosci 25 (2005) 9773-9781
58. Gibb W.R.G., and Lees A.J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 54 (1991) 388-396
59. Latchman D.S., and Coffin R.S. Viral vectors in the treatment of Parkinson's disease. Mov Disord 15 (2000) 9-17
60. Mandir A.S., Dawson V.L., and Dawson T.M. Gene therapy to the rescue in Parkinson's disease. Trends Pharmaol Sci 22 (2001) 103-105
61. Kneuer C., Sameti M., Haltner E.G., Schiestel T., Schirra H., Schmidt H., et al. Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA. Int J Pharm 196 (2000) 257-261
62. Kneuer C., Sameti M., Bakowsky U., Schiestel T., Schirra H., Schmidt H., et al. A nonviral DNA delivery system based on surface modified silica-nanoparticles can efficiently transfect cells in vitro. Bioconjug Chem 11 (2000) 926-932
63. Carlsson T., Winkler C., Burger C., Muzyczka N., Mandel R.J., Cenci A., et al. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous l-DOPA delivery using rAAV vectors. Brain 128 (2005) 559-569
64. Available from: http://www.clinicaltrials.gov/ct/show/NCT00229736.
65. During M.J., Kaplitt M.G., Stern M.B., and Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 12 (2001) 1589-1591
66. Airaksinen M.A., and Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nature Rev Neurosci 3 (2002) 383-394
67. Wagner J., Akerund P., Castro D.S., Holm P.C., Canals J.M., Snyder E.Y., et al. Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. Nat Biotechnol 17 (1999) 653-659
68. Zhang Y., Calon F., Zhu C., Boado R.J., and Pardridge W.M. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 14 (2003) 1-12
69. Fu A., Gu W., Larabell C., and Alivisatos A.P. Semiconductor nanocrystals for biological imaging. Curr Opin Neurobiol 15 (2005) 568-575
70. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., Dumuchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 (2001) 710-719
71. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., and Brin M.F. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 (2003) 403-414
72. Björklund A., and Lindvall O. Cell replacement therapies for central nervous system disorders. Nature Neurosci 3 (2000) 537-544
73. Winkler C., Kirik D., and Björklund A. Cell transplantation in Parkinson's disease. How can we make it work?. Trends Neurosci 28 (2005) 86-92
74. Orive G., Hernández R.M., Gascón A.R., Calafiore R., Chang T.M.S., De Vos P., et al. Cell encapsulation: promise and progress. Nat Med 9 (2003) 104-107
75. Grandoso L., Ponce S., Manuel I., Ruiz Ortega J.A., Hernandez R., Linazasoro G., et al. Striatal implantation of encapsulated GDNF secreting cells improves behavioural abnormalities in a rat model of Parkinson's disease. Int J Pharm 343 (2007) 69-78
76. Jollivet C., Aubert-Pouessel A., Clavreul A., Venier-Julienne M.C., Remy S., Montero-Menei C.N., et al. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. Biomaterials 25 (2004) 933-942
77. Kishima H., Poyot T., Bloch J., Dauguet J., Condé F., Dollé F., et al. Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a preclinical study in chronic MPTP-treated baboons. Neurobiol Dis 16 (2004) 428-439
78. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59 (2006) 459-466
79. Barker R.A. Continuing trials of GDNF in Parkinson's disease. Lancet Neurol 5 (2006) 285-286
80. Subramanian T., Marchionini D., Potter E.M., and Cornfeldt M.L. Striatal xenotransplantation of human retinal pigment epithelial cells attached to microcarriers in hemiparkinsonian rats ameliorates behavioral deficits without provoking a host immune response. Cell Transplant 11 (2002) 207-214
81. Stover N.P., Bakay R.A.E., Subramanian T., Raiser C.D., Cornfeldt M.L., Schweikert A.W., et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch Neurol 62 (2005) 1833-1837
82. Windebank A, Yaszemski M. Biodegradable implant as scaffold for nerve regrowth. Abstract at American Academy of Neurology annual meeting. May 2004 S66.006.
83. Silva G.A., Czeisler C., Niece K.L., Beniash E., Harrington D.A., Kessler J.A., et al. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 303 (2004) 1252-1255
84. Woerly S., Doan V.D., Evans-Martin F., and Paramore C.G. Spinal cord reconstruction using NeuroGel implants and functional recovery after chronic injury. J Neurosci Res 66 (2001) 1187-1197
85. Méndez I., Dagher A., Hong M., Gaudet P., Weerasinghe S., McAlister V., et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson's disease: a pilot study. Report of three cases. J Neurosurg 96 (2002) 589-596
86. Chiang Y.H., Lin S.Z., and Zhou F.C. Bridging nigrostriatal pathway with fibroblast growth factor-primed peripheral nerves and fetal ventral mesencephalon transplant recuperates from deficits in parkinsonian rats. Cell Transplant 15 (2006) 475-482
87. Novikova L.N., Novikov L.N., and Kellerth J.O. Biopolymers and biodegradable smart implants for tissue regeneration after spinal cord injury. Curr Opin Neurol 16 (2003) 711-715
88. Borgens R.B., and Bohnert D. Rapid recovery from spinal cord injury after subcutaneously administered polyethylene glycol. J Neurosci Res 66 (2001) 1179-1186
89. Ellis-Behnke R.G., Liang Y.X., You S.W., Tay D.K.C., Zhang S., So K.F., et al. Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci U S A 103 (2006) 5054-5059
90. Geraerts M., Krylychkina O., Baekelandt V., and Debyser Z. Therapeutic strategies for Parkinson's disease based on the modulation of adult neurogenesis. Stem Cells (2006) 10.1634/stemcells.2006-0364
91. Moon L.D., Asher R.A., Rhodes K.E., and Fawcett J.W. Regeneration of CNS axons back to their target following treatment of adult rat brain with chondroitinase ABC. Nature Neurosci 4 (2001) 465-466
92. Buffo A. Expression pattern of the transcription factor Olig2 in response to brain injuries: implications for neuronal repair. Proc Natl Acad Sci U S A 102 (2005) 18183-18188
93. Sawamoto K., Wichterle H., Gonzalez-Perez O., Cholfin J.A., Yamada M., Spassky N., et al. New neurons follow the flow of cerebrospinal fluid in the adult brain. Science (2006) 629-632 311
94. Mahoney M.J., and Saltzman W.M. Transplantation of brain cells assembled around a programmable synthetic microenvironment. Nat Biotechnol 19 (2001) 934-939
95. Zaghoul K.A., and Boahen K. Optic nerve signals in a neuromorphic chip. IEEE Trans Biomed Eng 51 (2004) 657-675
96. Lockwood N.A., Mohr J.C., Ji L., Murphy C.J., Palecek S.P., de Pablo J.J., et al. Thermotropic liquid crystals as substrates for imaging the reorganization of matrigel by human embryonic stem cells. Adv Funct Mat 16 (2005) 618-624
97. Borm P.J., Robbins D., Haubold S., Kuhlbusch T., Fissan H., Donaldson K., et al. The potential risks of nanomaterials: a review carried out for ECETOC. Part Fibre Toxicol 3 (2006) 11